Effect of vildagliptin and pravastatin combination on cholesterol efflux in adipocytes

Ahmed M. Mostafa, Nadia M. Hamdy, Sherif Abdel-Rahman, Hala O. El-Mesallamy

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Many reports suggested that some statins are almost ineffective in reducing triglycerides or enhancing HDL-C plasma levels, although statin treatment was still efficacious in reducing LDL-C. In diabetic dyslipidemic patients, it may therefore be necessary to use a combination therapy with other drugs to achieve either LDL-C- and triglyceride-lowering or HDL-C-enhancing goals. Such ineffectiveness of statins can be attributed to their effect on the liver X receptor (LXR) which regulates the expression of the ATP-binding cassette (ABC) transporters ABCA1 and ABCG1. A decrease in the expression of these transporters eventually leads to decreased cholesterol efflux from peripheral tissues leading to low levels of HDL-C. Although manipulating the LXR pathway may complement the effects of statins, LXR synthetic ligands as T091317 have shown significant hypertriglyceridemic action which limits their use. We recently found that the antidiabetic drug vildagliptin stimulates LXR expression leading to increased ABCB1/ABCG1 expression which improves cholesterol efflux from adipocytes. Therefore, a combination of vildagliptin and statin may provide a solution without the hypertriglyceridemic action observed with LXR agonist. We hypothesize that a combination of vildagliptin and pravastatin will improve cholesterol efflux in adipocytes. Statin-treated 3T3-L1 adipocytes were treated with vildagliptin, and the expression of LXR-ABCA1/ABCG1 cascade and the cholesterol efflux were then determined. Our data indicate that a combination of vildagliptin and pravastatin significantly induces the expression of LXR-ABCA1/ABCG1 cascade and improves cholesterol efflux (P > 0.05) in adipocytes. Our data may explain, at least in part, the improvement in HDL-C levels observed in patients receiving both medications.

Original languageEnglish (US)
Pages (from-to)535-543
Number of pages9
JournalIUBMB Life
DOIs
StatePublished - Jul 1 2016

Fingerprint

Pravastatin
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Adipocytes
Liver
Cholesterol
Triglycerides
Artificial Receptors
ATP-Binding Cassette Transporters
vildagliptin
Liver X Receptors
Hypoglycemic Agents
Tissue
Ligands
Plasmas
Therapeutics
Pharmaceutical Preparations

Keywords

  • ABC transporters
  • adipocytes
  • cholesterol
  • pravastatin
  • vildagliptin

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Clinical Biochemistry
  • Molecular Biology
  • Genetics

Cite this

Effect of vildagliptin and pravastatin combination on cholesterol efflux in adipocytes. / Mostafa, Ahmed M.; Hamdy, Nadia M.; Abdel-Rahman, Sherif; El-Mesallamy, Hala O.

In: IUBMB Life, 01.07.2016, p. 535-543.

Research output: Contribution to journalArticle

Mostafa, Ahmed M. ; Hamdy, Nadia M. ; Abdel-Rahman, Sherif ; El-Mesallamy, Hala O. / Effect of vildagliptin and pravastatin combination on cholesterol efflux in adipocytes. In: IUBMB Life. 2016 ; pp. 535-543.
@article{961bdd3e677c4dbe950d84a6a2e7ed2e,
title = "Effect of vildagliptin and pravastatin combination on cholesterol efflux in adipocytes",
abstract = "Many reports suggested that some statins are almost ineffective in reducing triglycerides or enhancing HDL-C plasma levels, although statin treatment was still efficacious in reducing LDL-C. In diabetic dyslipidemic patients, it may therefore be necessary to use a combination therapy with other drugs to achieve either LDL-C- and triglyceride-lowering or HDL-C-enhancing goals. Such ineffectiveness of statins can be attributed to their effect on the liver X receptor (LXR) which regulates the expression of the ATP-binding cassette (ABC) transporters ABCA1 and ABCG1. A decrease in the expression of these transporters eventually leads to decreased cholesterol efflux from peripheral tissues leading to low levels of HDL-C. Although manipulating the LXR pathway may complement the effects of statins, LXR synthetic ligands as T091317 have shown significant hypertriglyceridemic action which limits their use. We recently found that the antidiabetic drug vildagliptin stimulates LXR expression leading to increased ABCB1/ABCG1 expression which improves cholesterol efflux from adipocytes. Therefore, a combination of vildagliptin and statin may provide a solution without the hypertriglyceridemic action observed with LXR agonist. We hypothesize that a combination of vildagliptin and pravastatin will improve cholesterol efflux in adipocytes. Statin-treated 3T3-L1 adipocytes were treated with vildagliptin, and the expression of LXR-ABCA1/ABCG1 cascade and the cholesterol efflux were then determined. Our data indicate that a combination of vildagliptin and pravastatin significantly induces the expression of LXR-ABCA1/ABCG1 cascade and improves cholesterol efflux (P > 0.05) in adipocytes. Our data may explain, at least in part, the improvement in HDL-C levels observed in patients receiving both medications.",
keywords = "ABC transporters, adipocytes, cholesterol, pravastatin, vildagliptin",
author = "Mostafa, {Ahmed M.} and Hamdy, {Nadia M.} and Sherif Abdel-Rahman and El-Mesallamy, {Hala O.}",
year = "2016",
month = "7",
day = "1",
doi = "10.1002/iub.1510",
language = "English (US)",
pages = "535--543",
journal = "IUBMB Life",
issn = "1521-6543",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Effect of vildagliptin and pravastatin combination on cholesterol efflux in adipocytes

AU - Mostafa, Ahmed M.

AU - Hamdy, Nadia M.

AU - Abdel-Rahman, Sherif

AU - El-Mesallamy, Hala O.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Many reports suggested that some statins are almost ineffective in reducing triglycerides or enhancing HDL-C plasma levels, although statin treatment was still efficacious in reducing LDL-C. In diabetic dyslipidemic patients, it may therefore be necessary to use a combination therapy with other drugs to achieve either LDL-C- and triglyceride-lowering or HDL-C-enhancing goals. Such ineffectiveness of statins can be attributed to their effect on the liver X receptor (LXR) which regulates the expression of the ATP-binding cassette (ABC) transporters ABCA1 and ABCG1. A decrease in the expression of these transporters eventually leads to decreased cholesterol efflux from peripheral tissues leading to low levels of HDL-C. Although manipulating the LXR pathway may complement the effects of statins, LXR synthetic ligands as T091317 have shown significant hypertriglyceridemic action which limits their use. We recently found that the antidiabetic drug vildagliptin stimulates LXR expression leading to increased ABCB1/ABCG1 expression which improves cholesterol efflux from adipocytes. Therefore, a combination of vildagliptin and statin may provide a solution without the hypertriglyceridemic action observed with LXR agonist. We hypothesize that a combination of vildagliptin and pravastatin will improve cholesterol efflux in adipocytes. Statin-treated 3T3-L1 adipocytes were treated with vildagliptin, and the expression of LXR-ABCA1/ABCG1 cascade and the cholesterol efflux were then determined. Our data indicate that a combination of vildagliptin and pravastatin significantly induces the expression of LXR-ABCA1/ABCG1 cascade and improves cholesterol efflux (P > 0.05) in adipocytes. Our data may explain, at least in part, the improvement in HDL-C levels observed in patients receiving both medications.

AB - Many reports suggested that some statins are almost ineffective in reducing triglycerides or enhancing HDL-C plasma levels, although statin treatment was still efficacious in reducing LDL-C. In diabetic dyslipidemic patients, it may therefore be necessary to use a combination therapy with other drugs to achieve either LDL-C- and triglyceride-lowering or HDL-C-enhancing goals. Such ineffectiveness of statins can be attributed to their effect on the liver X receptor (LXR) which regulates the expression of the ATP-binding cassette (ABC) transporters ABCA1 and ABCG1. A decrease in the expression of these transporters eventually leads to decreased cholesterol efflux from peripheral tissues leading to low levels of HDL-C. Although manipulating the LXR pathway may complement the effects of statins, LXR synthetic ligands as T091317 have shown significant hypertriglyceridemic action which limits their use. We recently found that the antidiabetic drug vildagliptin stimulates LXR expression leading to increased ABCB1/ABCG1 expression which improves cholesterol efflux from adipocytes. Therefore, a combination of vildagliptin and statin may provide a solution without the hypertriglyceridemic action observed with LXR agonist. We hypothesize that a combination of vildagliptin and pravastatin will improve cholesterol efflux in adipocytes. Statin-treated 3T3-L1 adipocytes were treated with vildagliptin, and the expression of LXR-ABCA1/ABCG1 cascade and the cholesterol efflux were then determined. Our data indicate that a combination of vildagliptin and pravastatin significantly induces the expression of LXR-ABCA1/ABCG1 cascade and improves cholesterol efflux (P > 0.05) in adipocytes. Our data may explain, at least in part, the improvement in HDL-C levels observed in patients receiving both medications.

KW - ABC transporters

KW - adipocytes

KW - cholesterol

KW - pravastatin

KW - vildagliptin

UR - http://www.scopus.com/inward/record.url?scp=84975246892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975246892&partnerID=8YFLogxK

U2 - 10.1002/iub.1510

DO - 10.1002/iub.1510

M3 - Article

SP - 535

EP - 543

JO - IUBMB Life

JF - IUBMB Life

SN - 1521-6543

ER -